Antibody-drug conjugates (ADCs) are targeted biological drugs composed of monoclonal antibodies and small molecule anti-tumor drugs in a characteristic connection manner. Using monoclonal antibodies as carriers, highly lethal small molecule tumor drugs are delivered to tumor cells in a targeted manner, playing a role in killing tumor cells. ADC, with its precise drug delivery targeting performance, reduces the toxic reactions of chemotherapy drugs, improves treatment efficacy, and provides a new option for patients with poor efficacy and intolerance to traditional chemotherapy treatment. With the continuous deepening of research, ADC has achieved good application results in various solid tumor clinical applications, and provided a new treatment plan for gastric cancer patients who have failed conventional chemotherapy. Therefore, in-depth analysis of ADC molecular structure, mechanism of action, indications in clinical application, medication regimen selection, and safety management is of great significance for the rational clinical use of such drugs. This article reviews the molecular structure, mechanism of action, research progress of novel ADCs, and application of ADCs in gastric cancer patients, in order to provide a reference for the rational clinical use of ADC drugs.

1.Shi D, Yang Z, Cai Y, et al. Research advances in the molecular classification of gastric cancer[J]. Cell Oncol (Dordr), 2024, 47(5): 1523-1536. DOI: 10.1007/s13402-024-00951-9.

2.Luo Q, Liu N, Pu S, et al. A review on the research progress on non-pharmacological therapy of Helicobacter pylori[J]. Front Microbiol, 2023, 14(1): 2771-2776. DOI: 10.3389/fmicb.2023.1134254.

3.Sun QW, Hong HS. Research progress on gene synthesis and anticancer and lipid-lowering mechanism of monacolin K[J].Anticancer Agents Med Chem, 2023, 29(1): 281-287. DOI: 10.2174/1871520623666230207122157.

4.Bellott E. ADCs-the magic bullet[J]. Sci Am, 2024, 28(6): 52-53. DOI: 10.1038/scientificamerican0296-92.

5.杨慧欣, 钱莹莹, 黄旭, 等. 抗HER2乳腺癌ADC药物研究进展[J]. 中国老年学杂志, 2023, 43(2): 500-506. [Yang HX, Qian YY, Huang X, et al. Research progress of anti HER2 breast cancer ADC drugs[J]. Chinese Journal of Gerontology, 2023, 43(2): 500-506.] DOI: 10.3969/j.issn.1005-9202.2022.02.064.

6.Gu DE, Kwon WS, Lee CK, et al. Exploration of different immunogenomic TMEs in gastric cancer based on HER2 and PD-L1 expression[J]. J Clin Oncol, 2024, 42(1): 1607-1613. DOI: 10.1200/JCO.2024.42.16_suppl.e16073.

7.中国抗癌协会肿瘤药物临床研究专业委员会, 国家抗肿瘤药物临床应用监测专家委员会, 国家肿瘤质控中心乳腺癌专家委员会, 等. 抗体药物偶联物治疗恶性肿瘤临床应用专家共识（2020版）[J]. 中华肿瘤杂志, 2021, 43(1): 1214-1227. [The Clinical Research Committee of Cancer Drugs of the Chinese Anti Cancer Association, the National Expert Committee on Clinical Application Monitoring of Anti tumor Drugs, the breast cancer Expert Committee of the National Cancer Quality Control Center, etc Expert Consensus on the Clinical Application of Antibody Drug Conjugates in the Treatment of Malignant Tumors (2020 Edition)[J]. Chinese Journal of Oncology, 2021, 43(1): 1214-1227 DOI: 10.3760/cma.j.cn112152-20201112-00981.

8.Chen X, Liu Y, Ren L, et al. Extraction, purification, structural characteristics and biological properties of the polysaccharides from Armillaria mellea (Vahl) P. Kumm.: A review[J]. Int J Biol Macromol, 2024, 259(12): 1811-1817. DOI: 10.1016/j.ijbiomac.2023.129175.

9.曾弘烨, 宁文静, 罗文新. ADC药物的抗体组成及其作用靶点研究进展[J]. 中国生物工程杂志, 2022, 42(5): 69-80. [Zeng HY, Ning WJ, Luo WX. Research progress on antibody composition and target of ADC drugs[J]. China Biotechnology , 2022, 42(5): 69-80.] DOI: 10.13220/j.cnki.jipr.2014.01.006.

10.Moreira ASP, Gaspar D, Ferreira SS, et al. Water-soluble saccharina latissima polysaccharides and relation of their structural characteristics with in vitro immunostimulatory and hypocholesterolemic activities[J]. Mar Drugs, 2023, 21(3): 183. DOI: 10.1016/j.carbpol.2019.115381.

11.Kuru H, Kkar H, Alper M. Effect of deposition potential and saccharin addition on structural, magnetic and magnetoresistance characteristics of NiCoFeCu films[J]. Z Naturforsch C Biosci, 2023, 28(2): 773-779. DOI: 10.1515/zna-2023-0137.

12.Garcia-Illescas D, Mazzeo R, Garcia-Duran C, et al. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era[J]. Curr Opin Obstet Gynecol, 2024, 36(2): 104-111. DOI: 10.1097/GCO.0000000000000934.

13.Xu W, Bano N, Guzman-Valdes O, et al. Development and validation of a cell-based binding neutralizing antibody assay for an antibody-drug conjugate[J]. AAPS J, 2024, 26(3): 37. DOI: 10.1208/s12248-024-00909-7.

14.曾天星, 田婵婵, 赵明栋, 等. 抗体偶联药物在非小细胞肺癌中的研究进展[J]. 临床肺科杂志, 2024, 29(5): 785-791. [Zeng TX, Tian CC, Zhao MD, et al. Research progress of antibody conjugated drugs in non-small cell lung cancer[J]. Journal of Clinical Pulmonary Medicine, 2024, 29(5): 785-791.] DOI: 10.3969/j.issn.1009-6663.2024.05.026.

15.Eke AC, Gebreyohannes RD, Pillai FVC. Physiologic changes during pregnancy and impact on small-molecule drugs, biologic (Monoclonal Antibody) disposition, and response[J]. J Clin Pharmacol, 2023, 63(1): 34-50. DOI: 10.1002/jcph.2227.

16.Nakajima T, Nagano K, Fukuda Y, et al. Subvisible particles derived by dropping stress enhance anti-peg antibody production and clearance of PEGylated proteins in mice[J]. J Pharm Sci, 2022, 111(5): 1363-1369. DOI: 10.1016/j.xphs.2022.01.023.

17.李雨凝, 苏佳琳, 谭树华, 等. 癌症治疗中新型抗体偶联药物的研究进展[J].中南大学学报（医学版）, 2024, 49(2): 296-304. [Li YN, Su JL, Tan SH, et al. Research progress on novel antibody conjugated drugs in cancer treatment[J]. Journal of Central South University (Medical Science), 2024, 49(2): 296-304. DOI: 10.11817/j.issn.1672-7347.2024.230418.

18.翟怡心, 许子宜, 谢同济, 等. 抗体偶联药物在实体瘤治疗中的研究进展[J]. 中国肿瘤临床与康复, 2023, 30(2): 92-98. [Zhai YX, Xu ZY, Xie TJ, et al. Research progress of antibody conjugated drugs in the treatment of solid tumors[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2023, 30(2): 92-98.] DOI: 10.13455/j.cnki.cjcor.113494-20221222-0012.

19.Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659. DOI: 10.1016/j.annonc.2023.05.008.

20.Peng Z, Liu J, Dai W, et al. Abstract 5312: BSI-082, a fully human anti-SIRPα antibody with both high specificity and broad coverage of SIRPα variant populations[J]. Cancer Res, 2022, 28(1): 1538-1545. DOI: 10.1158/1538-7445.AM2022-5312.

21.Pegram MD, Hamilton EP, Tan AR, et al. First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer[J]. Mol Cancer Ther, 2021, 37(8): 1442-1453. DOI: 10.1158/1535-7163.MCT-20-0014.

22.de Goeii BECG, Vink T, Ten Napel H, et al. Efficient payloaddelivery by a bispecific antibody-drug conjugate targetingHER2 and CD63[J]. Mol Cancer Ther, 2016, 15(11): 2688-2697. DOI: 10.1158/1535-7163.MCT-16-0364.

23.Khandare J, Bharde AA, Jayant S, et al. Abstract 6684: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients[J]. Cancer Res, 2023, 28(11): 1158-1164. DOI: 10.1158/1538-7445.AM2023-6684.

24.Leslie AT, Saleh M, Soni N, et al. Importance of establishing antibody specificity in multisystem inflammatory syndrome in newborn during the COVID-19 pandemic[J]. Acta Paediatr, 2023, 112(2): 303-304. DOI: 10.1111/apa.16345.

25.Makowski EK, Kinnunen PC, Huang J, et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space[J]. Nat Commun, 2022, 13(6): 2730-2738. DOI: 10.1038/s41467-022-31457-3.

26.Tripathy D, Ali K, Agrawal L, et al. ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).[J]. J Clin Oncol, 2024, 42(16): 1123-1127. DOI: 10.1200/JCO.2024.42.16_suppl.TPS1123.

27.Li Q, Cheng Y, Tong Z, et al. HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial[J]. Nat Commun, 2024, 15(1): 281-289. DOI: 10.1038/s41467-024-48798-w.

28.Natarajan SK, Danansezhian JC, Thummar VMP. Favorable outcome and safety of neoadjuvant trastuzumab emtansine (T-DM1) in a HER2-Positive early breast cancer patient with severe renal disease on hemodialysis ineligible for conventional chemotherapy: a case report[J]. Reports, 2023, 6(1): 1382-1394. DOI: 10.1158/0008-5472.SABCS13-P2-15-03.

29.王子源, 何晓波. 靶向EGFR的抗体药物偶联物治疗肿瘤的研究进展[J]. 中国肿瘤生物治疗杂志, 2023, 30(9): 842-847. [Wang ZY, He XB. Research progress on antibody drug conjugates targeting EGFR for the treatment of tumors[J]. Chinese Journal of Cancer Biotherapy, 2023, 30(9): 842-847. DOI: 10.12019/j.issn.1671-5144.202502018.

30.Levengood MR, Zhang XQ, Emmerton KK, et al. Abstract development982: of homogeneousdual-drug ADCs: application to the co-delivery of auristatin payloads withcomplementary antitumor activitiesI[J]. Cancer Res, 2017, 77(13 Supplement): 982. https://doi.org/10.1158/1538-7445am2017-982.

31.Levengood MR, Zhang XQ, Emmerton KK, et al. Abstract982:  development of homogeneous dual-drug ADCs: application to the co-delivery of auristatin payloads with complementary antitumor activities[J]. Cancer Res, 2022, 77(13): 982-989. DOI: 10.1158/1538-7445.AM2017-982.

32.田爱军, 李佳霖, 汪春娅, 等. 抗体偶联药物非临床安全性评价毒性病理学检查关注点[J]. 药物评价研究, 2024, 47(8): 1678-1686. [Tian AJ, Li JL, Wang CY, et al. Non clinical safety evaluation of antibody conjugated drugs and focus on toxicity pathology examination[J]. Drug Evaluation Research, 2024, 47(8): 1678-1686.] DOI: 10.7501/j.issn.1674-6376.2024.08.002.

33.陈家宁, 张世纪, 苏春霞. 抗体偶联药物在非小细胞肺癌临床研究疗效与安全性的研究现状与进展[J]. 中华转移性肿瘤杂志, 2024, 7(3): 264-270. [Chen JN, Zhang SJ, Su CX. The current status and progress of clinical research on the efficacy and safety of antibody conjugated drugs in non-small cell lung cancer[J]. Chinese Journal of Metastatic Cancer, 2024, 7(3): 264-270. DOI: 10.3760/cma.jcn101548-20240130-00021.

34.Lin F, Chen L, Zhang H, et al. Bioorthogonal prodrug-antibody conjugates for on-target and on-demand chemotherapy[J]. CCS Chem, 2019, 1(2): 226-236. http://qikan.cqvip.com/Qikan/Article/Detail?id=7108057677.

35.陈俞伽, 游子怡, 熊婵鹓, 等. 抗体偶联药物合成过程中定点偶联技术的前沿进展[J]. 中国现代应用药学, 2024, 41(2): 261-276. [Chen YJ, You ZY, Xiong CU, et al. Frontier progress of site-specific coupling technology in the synthesis process of antibody conjugated drugs[J]. Chinese Journal of Modern Applied Pharmacy, 2024, 41(2): 261-276.] DOI: 10.16438/j.0513-4870.2020-1225.

36.Tian H, Yu L, Zhang M, et al. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy[J]. Colloids Surf B Biointerfaces, 2023, 228: 113400. DOI: 10.1016/j.colsurfb.2023.113400.

37.白婉婷, 扈金萍. 抗体偶联药物的药代动力学特征及其在消化道系统癌症治疗中的研究进展[J]. 药学学报, 2023, 58(9): 2632-2639. [Bai WT, Hu JP. Pharmacokinetic characteristics of antibody conjugated drugs and their research progress in the treatment of digestive system cancers[J]. Acta Pharmaceutica Sinica, 2023, 58(9): 2632-2639.] DOI: 10.16438/j.0513-4870.2023-0019.

38.Khatri A, Cobbina E, Cheng S, et al. Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC).[J]. J Clin Oncol, 2024, 42(16): 2053-2057. DOI: 10.1200/JCO.2024.42.16_suppl.e20537.

39.李森林, 李心远, 陈勇, 等. 维迪西妥单抗联合替雷利珠单抗在膀胱癌新辅助治疗中的疗效和安全性分析[J]. 中华泌尿外科杂志, 2023, 44(11): 812-817. [Li SL, Li XY, Chen  Y, et al. Efficacy and safety analysis of vidicizumab combined with tiralizumab in neoadjuvant treatment of bladder cancer[J]. Chinese Journal of Urology, 2023, 44(11): 812-817. DOI: 10.3760/cma.j.cn112330-20230616-00217.

40.Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J]. Gastric Cancer, 2021, 24(4): 913-925. DOI: 10.1007/s10120-021-01168-7.

41.Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junctioncancer: a single-arm phase II study[J]. Cancer Commun (Lond), 2021, 41(11): 1173-1182. DOI: 10.1002/cac2.12214.

42.武亚楠, 吴方, 侯艳红. 德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析[J]. 中国药房, 2024, 35(2): 204-209. [Wu YN, Wu F, Hou YH. Cost effectiveness analysis of the second-line treatment of HER2 positive metastatic breast cancer with dextrastuzumab versus emmettrastuzumab[J]. China Pharmacy, 2024, 35(2): 204-209. DOI: 10.6039/j.issn.1001-0408.2024.02.14.

43.Esfahani SA, Ferreira CDA, Rotile NJ, et al. HER3 PET imaging predicts response to pan receptor tyrosine kinase inhibition therapy in gastric cancer[J]. Mol Imaging Biol, 2022, 25(2): 353-362. DOI: 10.1007/s11307-022-01763-9.

44.Capone E, Lattanzio R, Gasparri F, et al. EV20/NMS-P945, a novel thienoindole based antibody-drug conjugate targeting HER-3 forsolid tumors[J]. Pharmaceutics, 2021, 13(4): 483. DOI: 10.3390/pharmaceutics13040483.

45.Prasad H, Mathew JKK, Visweswariah SS. Receptor guanylyl cyclase C and cyclic GMP in health and disease: perspectives and therapeutic opportunities[J]. Front Endocrinol (Lausanne), 2022, 13(5): 911-919. DOI: 10.3389/fendo.2022.911459.

46.张娣, 黎立喜, 马飞. 戈沙妥珠单抗在乳腺癌及其他实体瘤中临床应用的研究进展[J]. 癌症, 2022, 41(6): 253-258. [Zhang  D, Li LX, Ma F. Research progress of clinical application of gosartuzumab in breast cancer and other solid tumors[J]. Chinese Journal of Cancer, 2022, 41(6): 253-258. DOI: 10.12354/j.issn.1000-8179.2023.202220959.

47.Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, anovel anti-TROP2 antibody conjugated to topoisomerase inhibitor,demonstrated promising antitumor efficacy compared to IMMU-132[J]. Front Oncol, 2022, 12(4): 951-959. DOI: 10.3389/fonc.2023.1334938.

48.Almhanna K, Kalebic T, Cruz C, et al. Phase I study of theinvestigational anti-guanylyl cyclase antibody-drug conjugateTAK-264 (MLN0264) in adult patients with advancedgastrointestinal malignancies[J]. Clin Cancer Res, 2016, 22(20): 5049-5057. DOI: 10.1158/1078-0432.CCR-15-2474.

49.Nakayama I, Qi C, Chen Y, et al. Claudin 18.2 as a novel therapeutic target[J]. Nat Rev Clin Oncol, 2024, 21(5): 354-369. DOI: 10.1158/1078-0432.CCR-08-1547.

50.Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2023, 401(9): 1655-1668. DOI: 10.1016/S0140-6736(23)00620-7.

51.Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J]. Ann Oncol, 2021, 32(5): 609-619. DOI: 10.1016/j.annonc.2021.02.005.

52.Sabui S, Anthonymuthu S, Ramamoorthy K, et al. Effect of knocking out mouse Slc44a4 on colonic uptake of the microbiota-generated thiamine pyrophosphate and colon physiology[J]. Am J Physiol Gastrointest Liver Physiol, 2024, 327(1): 36-46. DOI: 10.1152/ajpgi.00065.2024.

53.Chu M, Huang J, Wang Q, et al. A Circadian Rhythm-related Signature to Predict Prognosis, Immune Infiltration, and Drug Response in Breast Cancer[J]. Curr Med Chem, 2025, 32(3): 608-626. DOI: 10.2174/0109298673320179240803071001.

54.Coveler AL, Ko AH, Catenacci DV, et al. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers[J]. Invest New Drugs, 2016, 34(3): 319-328. DOI: 10.1007/s10637-016-0343-x.